SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion

• Published in: The Journal of infectious diseases Vol. 224; no. 6; pp. 989 - 994
• Main Authors: Ferreira, Isabella A T M, Kemp, Steven A, Datir, Rawlings, Saito, Akatsuki, Meng, Bo, Rakshit, Partha, Takaori-Kondo, Akifumi, Kosugi, Yusuke, Uriu, Keiya, Kimura, Izumi, Shirakawa, Kotaro, Abdullahi, Adam, Agarwal, Anurag, Ozono, Seiya, Tokunaga, Kenzo, Sato, Kei, Gupta, Ravindra K
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 17.09.2021
• Subjects: Angiotensin-Converting Enzyme 2; Animals; Antibodies; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; BNT162 Vaccine; Chlorocebus aethiops; COVID-19 - immunology; COVID-19 - virology; COVID-19 Vaccines - immunology; HEK293 Cells; Humans; Immune Evasion; India; Major and Brief Reports; mRNA; Mutation; Protein Binding; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Serine Endopeptidases; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - chemistry; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Vaccines; Vero Cells; India; antibody escape; COVID-19; B.1.617; SARS-CoV-2; fitness; Indian variant; neutralizing antibodies; evasion; spike mutation; infectivity; resistance

Abstract The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and...